Dirk Schadendorf, MD

Articles by Dirk Schadendorf, MD

STARBOARD Triplet Yields 33-Month Median PFS in BRAF V600–Mutant Melanoma

ByDirk Schadendorf, MD

October 30th 2026

Dirk Schadendorf, MD, reviewed final STARBOARD data for encorafenib, binimetinib, and pembrolizumab in first-line BRAF V600–mutant melanoma.

Latest Updated Articles

Trending on CancerNetwork

Prior Regimen Did Not Affect Daraxonrasib Benefit in Pretreated Pancreatic Cancer

Petosemtamab/Pembrolizumab Improves OS in First-Line PD-L1–Positive HNSCC

Sacituzumab Govitecan PFS Benefit Holds Across Subgroups in Untreated mTNBC

What Are the Top Takeaways for Neuroendocrine Carcinoma From 2026 ESMO?

Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?